Discovery of 2-alkyl-1-arylsulfonylprolinamides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors

ACS Medicinal Chemistry Letters

Volumn 3, Issue 10, 2012, Pages 793-798

  Yu, Jianxin ^a   Liu, Haiyan ^a   Xia, Guangxin ^a,b   Liu, Lin ^a,b   Xu, Zhenmin ^a   Chen, Qian ^a   Ma, Chen ^a   Sun, Xing ^a   Xu, Jiajun ^a   Li, Hua ^a   Li, Ping ^a   Shi, Yufang ^a   Xiong, Bing ^b   Liu, Xuejun ^a   Shen, Jingkang ^a,b  

^a Shanghai Pharmaceutical Holding Co Ltd   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

11 hydroxysteroid dehydrogenase type 1; 2 alkylproline; enzyme inhibitor; metabolic syndrome; prolinamide; sulfonamide

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; OXIDOREDUCTASE INHIBITOR; PREDNISOLONE; PREDNISONE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

EID: 84867344815     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300144n     Document Type: Article

References (21)

1. Wang, M. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy Handb. Exp. Pharmacol. 2011, 203, 127-146
2. Saiah, E. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors Curr. Med. Chem. 2008, 15, 642-649
3. Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice J. Clin. Invest. 2003, 112, 83-90
4. Kim, S. H.; Bok, J. H.; Lee, J. H.; Kim, I. H.; Kwon, S. W.; Lee, G. B.; Kang, S. K.; Park, J. S.; Jung, W. H.; Kim, H. Y.; Rhee, S. D.; Ahn, S. H.; Bae, M. A.; Ha, D. C.; Kim, K. Y.; Ahn, J. H. Synthesis and biological evaluation of cyclic sulfamide derivatives as 11β-hydroxysteroid dehydrogenase 1 inhibitors ACS Med. Chem. Lett. 2012, 3, 88-93
5. Barf, T.; Vallgårda, J.; Emond, R.; Haeggstroem, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Roenquist-Nii, Y.; Oehman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 2002, 45, 3813-3815
6. Cheng, H.; Hoffman, J.; Le, P; Nair, S. K.; Cripps, S.; Matthews, J.; Smith, C.; Yang, M.; Kupchinsky, S.; Dress, K.; Edwards, M.; Cole, B.; Walters, E.; Loh, C.; Ermolieff, J.; Fanjul, A.; Bhat, G. B.; Herrera, J.; Pauly, T.; Hosea, N.; Paderes, G.; Rejto, P. The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 2897-2902
7. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice J. Exp. Med. 2005, 202, 517-527
8. Véniant, M. M.; Hale, C.; Hungate, R. W.; Gahm, K.; Emery, M. G.; Jona, J.; Joseph, S.; Adams, J.; Hague, A.; Moniz, G.; Zhang, J.; Bartberger, M. D.; Li, V.; Syed, R.; Jordan, S.; Komorowski, R.; Chen, M. M.; Cupples, R.; Kim, K. W., St.; Jean, D. J.; Johansson, L.; Henriksson, M. A.; Williams, M.; Vallgårda, J.; Fotsch, C.; Wang, M. Discovery of a potent, orally active 11.beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: Identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl- 5-methylthiazol-4(5H)-one (AMG 221) J. Med. Chem. 2010, 53, 4481-4487
9. Rosenstock, J.; Banarer, S.; Fonseca, V. A.; Inzucchi, S. E.; Sun, W.; Yao, W.; Hollis, G.; Flores, R.; Levy, R.; Williams, W. V.; Seckl, J. R.; Huber, R. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy Diabetes Care 2010, 33, 1516-1522
10. Courtney, R.; Stewart, P. M.; Toh, M.; Ndongo, M. N.; Calle, R. A.; Hirshberg, B. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor J. Clin. Endocrinol Metab. 2008, 93, 550-556
11. Feig, P. U.; Shah, S.; Hermanowski-Vosatka, A.; Plotkin, D.; Springer, M. S.; Donahue, S.; Thach, C.; Klein, E. J.; Lai, E.; Kaufman, K. D. Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome Diabetes Obes. Metab. 2011, 13, 498-504
12. http://www.astrazenecaclinicaltrials.com/other-drug-products/ in-development-drugs/AZD4017/.
13. Xia, G.; Liu, L.; Xue, M.; Liu, H.; Yu, J.; Li, P.; Chen, Q.; Xiong, B.; Liu, X.; Shen, J. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11β-hydroxysteroid dehydrogenase type 1 Mol. Cell. Endocrinol. 2012, 358, 46-52
14. Mundt, S.; Solly, K.; Thieringer, R.; Hermanowski-Vosatka, A. Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 Assay Drug Dev. Technol. 2005, 3, 367-375
15. Xia, G.; Xue, M.; Liu, L.; Yu, J.; Liu, H.; Li, P.; Wang, J.; Li, Y.; Xiong, B.; Shen, J. Potent and novel 11β-HSD1 inhibitors identified from shape and docking based virtual screening Bioorg. Med. Chem. Lett. 2011, 21, 5739-5744
16. Bhat, B. G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl- 4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys J. Pharmacol. Exp. Ther. 2008, 324 (1) 299-305
17. Vielhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K. A.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J. Med. Chem. 2003, 46, 2774-2789
18. Patel, J. R.; Shuai, Q.; Dinges, J.; Winn, M.; Pliushchev, M.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Pan, L.; Wagaw, S.; Engstrom, K.; Kerdesky, F. A.; Longenecker, K.; Judge, R.; Qin, W.; Imade, H. M.; Stolarik, D.; Beno, D. W. A.; Brune, M.; Chovan, L. E.; Sham, H. L.; Jacobson, P.; Link, J. T. Discovery of adamantane ethers as inhibitors of 11β-HSD1: Synthesis and biological evaluation Bioorg. Med. Chem. Lett. 2007, 17, 750-755
19. Roche, D.; Carniato, D.; Leriche, C.; Lepifre, F.; Christmann-Franck, S.; Graedler, U.; Charon, C.; Bozec, S.; Doare, L.; Schmidlin, F.; Lecomte, M.; Valeur, E. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type I Bioorg. Med. Chem. Lett. 2009, 19, 2674-2678
20. Julian, L. D.; Wang, Z.; Bostick, T.; Caille, S.; Choi, R; DeGraffenreid, M.; Di, Y.; He, X.; Hungate, R. W.; Jaen, J. C.; Liu, J.; Monshouwer, M.; McMinn, D.; Rew, Y.; Sudom, A.; Sun, D.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model J. Med. Chem. 2008, 51, 3953-3960
21. Sakaguchi, K.; Yamamoto, M.; Watanabe, Y.; Ohfune, Y. Tetrahedron Lett. 2007, 48, 4821-4824